Background: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is known
| INTRODUCTION
Although asthma was traditionally believed to result from inflammation driven by T-helper type 2 (Th2) responses, 1,2 recent studies have focused on the highly heterogeneous features of this disease, including multiple phenotypes and endotypes. 3, 4 However, airway inflammation itself has been rarely measured in clinics, and the inflammatory process remains inconsistently identified. 5 Recently, biomarkers such as fractional exhaled nitric oxide (FeNO), 6 sputum eosinophil count, 7, 8 and serum periostin 9 for the determination and treatment of specific asthma subtypes are being emphasized. 10, 11 Human tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a type II-transmembrane protein that can be cleaved to function as a soluble cytokine, 12 is expressed in various cell types, including inflammatory cells, such as monocytes, macrophages, dendritic cells, T cells, and NK cells. 13 TWEAK acts through its highly inducible receptor, fibroblast growth factor-inducible 14 (Fn14), and plays a multifunctional role by regulating diverse cellular responses, including pro-inflammatory activity, cell growth, angiogenesis, modulation of progenitor cell biology, and even cell death. 13 It is significantly elevated in inflammatory diseases [14] [15] [16] and cancer, 17 which are associated with infiltration of inflammatory cells or activation of resident innate immune cells.
A few studies [18] [19] [20] have investigated the effect of TWEAK/Fn14 signaling on human bronchial epithelial cells and suggested its possible contribution to the development of airway inflammation. However, there has been no report on the expression of TWEAK in patients with respiratory diseases. Thus, we planned to evaluate the airway TWEAK levels in children with asthma, investigate the associations with sputum analysis and pulmonary function test (PFT) parameters, and potentially explain the specific subtypes of asthma. Healthy control subjects consisted of children who had visited the hospital for a general health checkup or vaccination and had normal lung function without BHR and never had a physician diagnosis of asthma.
| METHODS

| Study design
Children with concurrent diagnosis of other respiratory diseases or a parenchymal lung disease evident on chest radiography performed within 4 weeks were excluded. After clinical assessment, PFT with BD response, sputum induction, and blood sampling were performed on the same day, followed by a methacholine challenge test (MCT).
The study was approved by the institutional review board (IRB) of Severance Hospital (Seoul, Korea; IRB no. 4-2004-0036) . Written informed consent was obtained from the participants and their parents.
| Spirometry with impulse oscillometry (IOS) and MCT
Spirometry and MCT were executed with a Jaeger MasterScreen PFT system (Jaeger Co., Würzburg, Germany) using standard techniques in compliance with the American Thoracic Society/European Respiratory 
| Sputum induction, analysis, and assessment of TWEAK levels
Sputum induction and processing were performed according to the protocol by Gibson et al 24 All children were instructed to rinse their mouths thoroughly with water to clear debris and squamous epithelial cells, after which they inhaled a 3% saline solution nebulized in an ultrasonic nebulizer (NE-U12; Omron Co., Tokyo, Japan) at maximum output at room temperature. Then, they were encouraged to cough deeply at 3 minute intervals. Spirometry was repeated thereafter, and when the FEV 1 had decreased to ≤80% of the post-BD baseline value, the child was required to wait until it returned to baseline values. Induced samples were kept at 4°C for ≤2 hour before further processing. Selected portions of the samples were dispersed with dithiothreitol (WACO Pure Chemical Industries Ltd., Osaka, Japan), and a total cell count was performed. We determined sputum viability with the trypan blue exclusion method to ensure adequate viability. Total cell counts were carried out using a hemocytometer, and slides were prepared with cytospin (Cytospin 3; Shandon, Tokyo, Japan) and stained with May-Grünwald-Giemsa solution for differential cell counts. An adequate specimen was defined as one producing countable cytospin slides for estimation for differential cell count, with minimal squamous contamination (<50%). 24 At least 400 inflammatory cells were counted for each specimen by two individuals who were blinded to the clinical details. Sputum inflammatory subtypes were categorized, according to the percentages of sputum eosinophils and neutrophils, as eosinophilic (sputum eosinophils ≥3%
and sputum neutrophils <61%) and non-eosinophilic (sputum neutrophils ≥61% or sputum eosinophils <3%) inflammation. 25 The supernatant was then stored at −70°C for subsequent TWEAK assay performed with enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN, USA).
| Laboratory and allergy screening tests
Complete blood count, including eosinophil count, and total and specific immunoglobulin E (IgE) levels were measured with the ADVIA 2120i hematology system with autoslide (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA) and Pharmacia CAP assay (Uppsala, Sweden), respectively. A specific IgE test was performed with six common allergens in Korea (two types of dust mites, egg white, cow's milk, German cockroach, and Alternaria alternata). We defined atopy as the presence of at least one positive allergen-specific IgE test result (sIgE≥0.7 KUa/L).
| Statistical analysis
Continuous data were reported as the mean (±standard deviations)
or median (interquartile range Correlations between TWEAK levels and PFT parameters were analyzed through Spearman's rank correlation test. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic accuracy and calculate the optimal cutoff level.
All statistical analyses were conducted with SPSS Statistics (version 22.0; IBM Corp., Armonk, NY, USA) and R (version 3.3.2; R Foundation for Statistical Computing, Vienna, Austria). P < .05 was considered statistically significant.
| RESULTS
| Subjects' characteristics
Of the 230 children enrolled, successful sputum induction was carried out in 196 subjects (85.2%). Among them, 35 subjects had inadequate samples of induced sputum, and the remaining 173 subjects were finally analyzed. pg/mL, P = .014; Figure 1C ). In correlation analysis, sputum TWEAK level showed significant positive correlations with asthma severity (r = .250, P = .015) and level of control (r = .389, P < .001). There were no significant associations between sputum TWEAK levels and sex or age (data not shown).
| Associations between sputum TWEAK levels and PFT parameters
Among the total population, FEV 1 , FEV 1 /FVC, PEF, FEF , and post-BD FEV 1 /FVC had significant negative correlations with TWEAK levels. Of the IOS parameters, AX, R5, and X5 revealed significant positive correlations with TWEAK levels (Table 2) . When the total subjects were further divided into the eosinophilic airway (EA) group (n = 44) and non-EA (NEA) group (n = 129), the NEA group demonstrated significant inverse correlation with FEF , and positive correlations with AX, R5, and X5. In the EA group, sputum TWEAK showed no significant associations with any PFT parameter ( Table 2) .
| Sputum TWEAK levels in children with asthma and healthy controls according to types of airway inflammation
In the NEA group, TWEAK level was significantly elevated in chil- 
| Associations between sputum TWEAK levels and PFT parameters according to types of airway inflammation
The demographic characteristics and clinical indices of the total subjects according to airway cellular phenotypes are summarized in Table   S1 . The subjects were subdivided into high and low TWEAK groups based on the optimal TWEAK cutoff level (263.0 pg/mL) obtained from ROC curve analysis (Fig. S1 ). In the total population, subjects with high TWEAK revealed significantly lower FEF (P = .001) and higher AX (P = .008) and X5 (P < .001) than those with low TWEAK ( Figure 3A ).
In the NEA group, similar findings with lower FEF 25-75 (P = .017) and higher AX (P < .001), R5-R20 (P = .025), and X5 (P < .001) were found in subjects with high TWEAK (Figure 3B ), whereas no significant differences were noted between the high and low TWEAK groups in the above parameters in subjects with EA inflammation (data not shown).
T A B L E 2 Correlations between sputum tumor necrosis factor-like weak inducer of apoptosis (TWEAK) levels and pulmonary function test (PFT) parameters
| Sputum TWEAK and FeNO
Among the total study population, sputum TWEAK showed no meaningful association with FeNO. In children with asthma, a significant 
| DISCUSSION
Sputum TWEAK levels were significantly elevated in children with asthma compared with healthy controls. TWEAK levels were notably increased in severe asthma and uncontrolled asthma. Furthermore, sputum TWEAK level was significantly correlated with PFT parameters reflecting airway obstruction, which was particularly prominent in subjects with NEA inflammation. Significant differences in FEF , AX, R5-R20, and X5 were noted between the high and low TWEAK groups within the NEA group, whereas no meaningful differences were found within the EA group. Correlation studies also showed significant associations of sputum TWEAK levels with PFT indices, asthma severity, and control status distinctively in the NEA group.
Tumor necrosis factor-like weak inducer of apoptosis signals through Fn14, which contains a TNF receptor-associated factor binding sequence, resulting in the activation of nuclear factor-κB signaling pathways, 26 which have been known to induce multiple cellular responses depending on the cell type and context. 13 It contributes to a physiological process promoting tissue repair after acute injury, whereas its persistent upregulation leads to pathological tissue degeneration and remodeling in chronic inflammation. 13 Since the first description from 1997, 12 there have been several animal and human studies that aimed to elucidate the role of the TWEAK/Fn14 pathway in inflammatory diseases, exemplified by rheumatoid arthritis, 14 systemic lupus nephritis, 15 multiple sclerosis, 16 and tumors. 17 Accordingly, a few studies reported associations between TWEAK and airway inflammation. Xu et al 18 reported that TWEAK stimulates F I G U R E 3 Distribution of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/PFT index values from subjects dichotomized into the high and low TWEAK groups. Gray vertical lines represent the TWEAK cutoff level (263.0 pg/mL) obtained from the receiver operating characteristic curve. Horizontal lines and shaded areas represent the mean ± standard deviation, or median and interquartile range in each group, respectively. The TWEAK axis (x-axis) is natural log-scaled. (A) In the total population, subjects of the high TWEAK group revealed significantly lower FEF , and higher AX and X5 than those of the low TWEAK group. (B) In children with non-eosinophilic airway inflammation, the high TWEAK group showed significantly lower FEF , and higher AX, R5-R20, and X5 than the low TWEAK group. TWEAK, tumor necrosis factor-like weak inducer of apoptosis; PFT, pulmonary function test; FEF , maximum mid-expiratory flow; AX, reactance area; R5-R20, difference between resistance at 5 Hz and 20 Hz; X5, reactance at 5 Hz human bronchial epithelial cells to produce pro-inflammatory IL-8
and granulocyte-macrophage colony-stimulating factor. They spec- Clinically, non-eosinophilic asthma, which is mainly characterized by neutrophilic airway inflammation, is frequently associated with severe asthma and steroid resistance, indicating the need for alternative treatment strategies. 5 However, much less is understood about the underlying phenotypes and molecular mechanisms compared with eosinophilic asthma. In the present study, the sputum TWEAK levels in children with asthma within the NEA group were higher with greater asthma severity and poorer control status and had significant positive correlations with these parameters. In contrast, there were no significant differences in TWEAK levels across subjects with asthma stratified according to severity and control status in the EA group, and no statistically significant correlations were noted. Accordingly, TWEAK may have a greater association with NEA inflammation, potentially explaining the underlying molecular process of non-eosinophilic asthma.
The correlation assay demonstrated a significant negative association between the sputum TWEAK level and the measured FeNO in asthmatic children. This correlation was distinctively statistically significant in asthmatics with NEA. Considering that FeNO is a well-established marker associated with eosinophilic airway inflammation in asthma, 6 the above findings further support the possible contribution of TWEAK in non-eosinophilic childhood asthma. A previous report of Nakayama et al, 27 which showed TWEAK expression from monocytes upon stimulation with γ-interferon, and a recent report of Bilgiç et al, 28 which identified elevated serum levels of TWEAK in patients with psoriasis vulgaris, a T-cell-mediated chronic inflammatory disease with a mixed Th1/Th17 cytokine environment, also support this association with non-Th2 immunity. Another study 29 In conclusion, sputum TWEAK levels were elevated in children with asthma, and significantly correlated with asthma severity, level of control, and indices of small airway obstruction, distinctively in children with NEA inflammation. We thus suggest that TWEAK may play a role in small airway inflammation in children with non-eosinophilic asthma.
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